Background: People living with HIV (PLHIV) in resource-limited settings are vulnerable to malnutrition. Nutritional interventions aimed at improving food insecurity and malnutrition, together with antiretroviral therapy (ART), could improve treatment outcomes. In Nigeria, there is a high awareness of the nutraceutical benefits of Moringa oleifera. Thus, this study aimed to evaluate the effects of Moringa oleifera leaf supplementation on the CD4 counts, viral load and anthropometric of HIV-positive adults on ART. Methods: This was a double-blind, randomized study. Two hundred HIV-positive patients were randomly allocated to either the Moringa Oleifera group (MOG) given Moringa oleifera leaf powder or the control group (COG) given a placebo. Changes in anthropometric parameters [weight; body mass index (BMI)] and CD4 cell counts were measured monthly for six months, while HIV-1 viral loads were measured at baseline and the end of the study for both groups. Results: Over the study period, the treatment by time interaction shows a significant difference in CD4 counts by treatment group (p<0.0001). A further estimate of fixed effects showed that the CD4 counts among MOG were 10.33 folds greater than COG over the study period. However, the viral load (p = 0.9558) and all the anthropometric parameters (weight; p = 0.5556 and BMI; p = 0.5145) between the two groups were not significantly different over time. All tests were conducted at 95CI. Conclusion: This study revealed that Moringa oleifera leaf supplementation was associated with increased CD4 cell counts of PLHIV on ART in a resource-limited setting. Programs in low-resource settings, such as Nigeria, should consider nutritional supplementation as part of a comprehensive approach to ensure optimal treatment outcomes in PLHIV.
To maintain an optimal nutritional status and immunological function in PLHIV, a diet with adequate nutrients is of utmost importance. This is a major challenge among poor populations in developing worlds like Nigeria, where malnutrition and food insecurity are endemic. This study aimed to assess the type of regular diet consumed and assess the impact of supplementation of the diet with Moringa oleifera Lam. leaves on the nutritional status and CD4 cell counts of PLHIV that are on ART in Nigeria. A double-blind, randomized trial was conducted. Two hundred consented patients were randomly allocated to either the Moringa oleifera Lam. group (MOG) or the control group (COG). The FAO individual dietary diversity questionnaire was used. The regular diets of participants at baseline and six months were monitored. The measurements of weight, BMI, MUAC, and CD4 cell counts were obtained from baseline to six months of Moringa oleifera Lam. leaves supplementation. One hundred and seventy-seven patients completed the six-month follow-up (89 MOG versus 88 COG). At both baseline and sixth month, the foods most commonly consumed by the participants in both MOG and COG were cereals, spices and condiments, oils, fats and palm oil, and dark green vegetables. At baseline, significantly higher consumption of legumes, nuts & seeds (p = 0.001) was observed in the MOG and higher consumption of other vegetables (p = 0.024) in COG. Consumption of cereals, roots, and tubers was significantly higher (p = 0.024; 0.045) in the COG in the sixth month. In both groups, participants were in the medium or low dietary diversity tercile. Throughout the study period, all the nutritional status variables observed were not significantly different between the two study groups [(p > 0.0001); weight; p = 0.5556; BMI; p = 0.5145; MUAC; p = 0.6456]. Over the study period, the treatment by time interaction shows a significant difference in CD4 counts by treatment group (p < 0.0001) and an estimate of fixed effects 10.33 folds greater in the MOG than COG. All tests were conducted at 95CI. This study revealed a poor dietary diversity amongst PLHIV. Supplementation of regular diet with Moringa oleifera Lam. leaves did not affect the nutritional status but could improve the immune response of HIV-positive adults attending the antiretroviral treatment centre in the present study area.
29 September 2022 in Journal of Public Health in Africa
Background. HIV-related weight loss and wasting were the most common malnutrition and AIDS-defining conditions before HAART. HAART has led to more obese PLHIV. HIV-positive patients should eat micro- and macronutrient-rich foods to maintain optimal nutrition. This study examined whether Moringa oleifera Lam. leaf supplementation affects PLHIV receiving ART.Methods. A randomized, double-blind, controlled trial was conducted. Two hundred patients with informed consent were randomly assigned to either the Moringa oleifera Lam. (MOG) group or the control group (COG). From baseline to six months of Moringa oleifera Lam. leaf supplementation, anthropometric parameters [weight; BMI] of the participants were assessed.Results. One hundred seventy-seven patients completed the 6-month follow-up (89 MOG versus 88 COG). During the study period, the MOG and COG had similar weights and BMIs (p0.05). At baseline and six months, most participants in both study groups had a healthy BMI (18.5-24.9). Many participants were overweight; few were underweight (BMI18.5). MOG and COG BMI differences at baseline and six months were not significant (p 0.05). All experiments were 95CI.Conclusions. Moringa oleifera Lam. leaf powder had no effect on HIV-positive adults receiving antiretroviral therapy, in accordance with this study.
Introduction: Participation of patients in well-designed clinical trials forms the essence of all clinical research. PLHIV and receiving ART at AKTH, Kano State, Nigeria, were invited to participate in a six-month Moringa oleifera Lam. supplementation study. One hundred and seventy-seven (177) patients participated, while 27 declined. This study assesses the perception and attitude to clinical trial participation as well as the refusal of the study participants. Methods: A questionnaire interview was conducted on those who participated and those who declined. Data was analysed using both descriptive and inferential statistics. Results: All the reasons for participation in clinical trials were statistically significant (p < 0.05). Reasons such as “To help myself” and “To improve my health” both have a perfect mean score of 1.0000 and a standard deviation of 0.0000, indicating reasons as the most important for participation. “To help others” (mean = 1.9379) and “Asked by the doctor” (mean = 2.4237) were moderately endorsed. “For the money” (mean = 3.0000) was the least supported among tangible reasons. Most participants understood the consent form, agreed they gained something from participating, felt respected and treated with dignity, trusted that their information would remain private, and believed the research would benefit others. Participation was largely seen as a free and meaningful choice. The most significant reasons cited for the lack of participation were time constraints (p = 0.029) and lack of money to come to the hospital for the study (p = 0.049). Discussion: Clinical trials can be conducted more quickly and effectively with greater patient participation. Improving awareness will improve patient participation and retention in clinical trials, which will invariably increase access to the newest available treatments.
Clinical trials are essential for validating the safety and efficacy of traditional medicines; however, their conduct in Africa is significantly hindered by resource constraints, a lack of standardized regulatory frameworks, and insufficient guidance for navigating complex ethical review processes. This study addresses the knowledge gap regarding the practical experience of obtaining multi-country regulatory and ethical approvals for herbal clinical trials. A qualitative case study design was employed to document the regulatory and ethical review processes for a randomized controlled trial of Moringa oleifera Lam. leaf supplementation in HIV-positive adults receiving antiretroviral therapy. Data were synthesized from institutional correspondence, ethical reviews, and communication records with the University of KwaZulu-Natal in South Africa, Aminu Kano Teaching Hospital, and the National Agency for Food and Drug Administration and Control in Nigeria. This study highlights the challenges of managing multi-country regulatory systems, particularly in the absence of harmonized guidelines for herbal research. The findings suggest that inter-institutional collaboration and adherence to rigorous Good Clinical Practice (GCP) standards are critical for the successful conduct of herbal trials. The review process revealed significant differences in turnaround times, documentation requirements, and query complexities across the involved institutions. In conclusion, this study emphasizes the need for regionally harmonized, risk-based regulatory frameworks for herbal medicines. Sharing practical experience is vital for building capacity. This enables researchers to better navigate institutional bureaucracies and advance high-quality clinical research in developing countries.